EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting Hsp90 in Cancer for 25 Years: Failure of Previous Clinical Trials and New Hope for Future Therapeutics

Mei Chen, Cheng Chang, Kathleen L Miao, David T Woodley, Wei Li iD

Cells · 2025

DOI: 10.3390/cells14241989 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2025. Verfasst von Mei Chen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Neoplasms, Antineoplastic Agents, Molecular Targeted Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Congressionally Directed Medical Research Programs, Congressionally Directed Medical Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

All previous IND (investigational new drug) applications to US FDA for launching clinical trials with Hsp90 ATP-binding inhibitors only provided a partial, if not misleading, account of the inhibitors’ actual MOA (mechanism of action). Since 2004, studies have repeatedly shown a previously unanticipated “extra effect” of these inhibitors, but it has been incomprehensively ignored by the Hsp90 community. Membrane-impermeable, otherwise structurally identical, ATP-binding Hsp90 inhibitors show robust inhibition of tumor cell invasion in vitro and metastasis in vivo. Based on this new finding, the reported outcomes of around 90 monotherapy clinical trials with Hsp90 ATP-binding inhibitors since 1999 were actually a combined effect of targeting both intracellular Hsp90 chaperone and extracellular Hsp90 (eHsp90) non-chaperone functions by the inhibitors. A critical unanswered question remains: which form of the dual inhibitions caused the observed toxicity in humans that led to the spectacular failure of the trials and which underlies the limited efficacy that might be the real reason for the only approval of the orally administered ATP-binding inhibitor, Pimitespib (TAS-116), in 2022 by Japan? We suggest that addressing this question could prompt a paradigm shift in the design of next-generation anti-Hsp90 cancer therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsNeoplasmsAntineoplastic AgentsMolecular Targeted TherapyHumansClinical Trials as TopicAnimals

Stichwörter der Autor:innen

cancer clinical trialsextracellular Hsp90intracellular Hsp90old and new generations of inhibitor therapeuticsparadigm shift

Substanzen

HSP90 Heat-Shock ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Dermatology, The Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.

ORCID-Profile: Wei Li

Förderung

  • Congressionally Directed Medical Research Programs
  • Congressionally Directed Medical Research Program

Zitieren

APA

Chen, M., Chang, C., Miao, K. L., Woodley, D. T., & Li, W. (2025). Targeting Hsp90 in Cancer for 25 Years: Failure of Previous Clinical Trials and New Hope for Future Therapeutics. Cells. https://doi.org/10.3390/cells14241989

Vancouver

Chen M, Chang C, Miao KL, Woodley DT, Li W. Targeting Hsp90 in Cancer for 25 Years: Failure of Previous Clinical Trials and New Hope for Future Therapeutics. Cells. 2025. doi:10.3390/cells14241989

BibTeX
@article{Chen2025,
  author = {Chen, Mei and Chang, Cheng and Miao, Kathleen L and Woodley, David T and Li, Wei},
  title = {Targeting Hsp90 in Cancer for 25 Years: Failure of Previous Clinical Trials and New Hope for Future Therapeutics},
  journal = {Cells},
  year = {2025},
  doi = {10.3390/cells14241989}
}
Kostenlos starten →